# K36 Therapeutics

Source: https://onco.cc/companies/k36-therapeutics/  
OnCo record `k36-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

K36 Therapeutics makes pills that block an enzyme called NSD2 (also known as MMSET), which is overactive in about one in five multiple myeloma cases because of a chromosome swap. It is also testing the approach in prostate cancer.

## Summary

K36 Therapeutics is a Cambridge, Massachusetts clinical-stage company and the first to target the histone methyltransferase NSD2 (MMSET/WHSC1). Gintemetostat (KTX-1001) is a first-in-class, oral, selective catalytic NSD2 inhibitor in the K36-MMSET-001 trial in relapsed or refractory multiple myeloma with the t(4;14) translocation; the company reports target engagement, an encouraging safety profile and clinical activity in heavily pretreated patients, with expansion cohorts combining it with carfilzomib, mezigdomide or pomalidomide. KTX-2001, a second oral NSD2 inhibitor, is in the K36-STRIKE-001 trial in metastatic castration-resistant prostate cancer alone and with darolutamide. K36 launched in December 2021 with a 30 million US dollar Series A co-led by F-Prime Capital and Atlas Venture, and raised a 70 million US dollar Series B in June 2023 led by Nextech Invest with Bristol Myers Squibb participating.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge, MA
- Type: biotech
- Website: https://www.k36tx.com/

## Notes

- No SEC Form D filings were found under the company name. Founding year not sourced.

## Sources

- Official website: https://www.k36tx.com/
- Series A press release (PR Newswire): https://www.prnewswire.com/news-releases/k36-therapeutics-launches-with-30-million-series-a-financing-from-f-prime-capital-and-atlas-venture-with-eight-roads-ventures-301440553.html
- Series B press release (PR Newswire): https://www.prnewswire.com/news-releases/k36-therapeutics-announces-70-million-series-b-financing-to-fund-clinical-proof-of-concept-of-ktx-1001-first-in-class-inhibitor-of-mmset-for-treatment-of-multiple-myeloma-patients-with-genetic-translocation-414-301865147.html

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- companies: [Atlas Venture](https://onco.cc/companies/atlas-venture/), [F-Prime Capital](https://onco.cc/companies/f-prime-capital/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/k36-therapeutics.json